[go: up one dir, main page]

AR024732A1 - METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS. - Google Patents

METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS.

Info

Publication number
AR024732A1
AR024732A1 ARP000103604A ARP000103604A AR024732A1 AR 024732 A1 AR024732 A1 AR 024732A1 AR P000103604 A ARP000103604 A AR P000103604A AR P000103604 A ARP000103604 A AR P000103604A AR 024732 A1 AR024732 A1 AR 024732A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
pain
treatment
cycloalkyl
Prior art date
Application number
ARP000103604A
Other languages
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR024732A1 publication Critical patent/AR024732A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)

Abstract

Un método para tratar el dolor cronico que comprende administrar a un sujeto que necesita tal tratamiento una composicion que comprende un inhibidor MEK.Un método para tratar el dolor cronico que comprende administrar a un sujeto que necesita tal tratamiento una composicion que comprende un inhibidor MEKseleccionado de un compuesto que se define mediante la formula 1, R1 es hidrogeno, hidroxi, alquilo C1-8, alcoxi C1-8, halo, trifluorometilo, o CN; R2 eshidrogeno; R3, R4 y R5 son independientemente hidrogeno, hidroxi, halo, trifluorometilo, alquilo C1-8, alcoxi C1-8, nitro, CN, o (O o NH)m-(CH2)n-R9, donde R9es hidrogeno, hidroxi, CO2H, o NR10R11; n es 0-4; m es 0-4; R10 y R11 son independientemente hidrogeno o alquilo C1-8, o tomados juntos con el nitrogeno alcual están unidos pueden completar un anillo cíclico de 3 a 10 miembros que opcionalmente contienen uno, dos o tres heteroátomos seleccioandos de O, S, NH oN-C1-8 alquilo; R6 es hidrogeno, alquilo C1-8, alquilo de O=C-C1-8, arilo, aralquilo o cicloalquilo C3-10; R7 es hidrogeno, alquilo C1-8, alquenilo C2-8,alquinilo C2-8, cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9; y donde cualquiera de los grupos alquilo, alquenilo, yalquinilo que anteceden pueden ser no sustituidos o sustituidos por cicloalquilo (o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9), arilo, ariloxi, heteroarilo, o heteroariloxi; o R6 y R7 tomados juntos con el N-O al que están unidos pueden completar un anillo cíclico de 5 a 10miembros, que opcionalmente contienen uno, dos o tres heteroátomos adicionales seleccionado de O, S, o NR10R11. Util en el campo del tratamiento del dolorcronico utilizando inhibidores de MEK. El dolorcronico incluye el dolor neuropático y el dolor por inflamacion cronica.A method for treating chronic pain that comprises administering to a subject in need of such treatment a composition comprising a MEK inhibitor. A method of treating chronic pain that comprises administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound defined by formula 1, R 1 is hydrogen, hydroxy, C 1-8 alkyl, C 1-8 alkoxy, halo, trifluoromethyl, or CN; R2 is hydrogen; R3, R4 and R5 are independently hydrogen, hydroxy, halo, trifluoromethyl, C1-8 alkyl, C1-8 alkoxy, nitro, CN, or (O or NH) m- (CH2) n-R9, where R9 is hydrogen, hydroxy, CO2H, or NR10R11; n is 0-4; m is 0-4; R10 and R11 are independently hydrogen or C1-8 alkyl, or taken together with the alkaline nitrogen they are attached can complete a cyclic ring of 3 to 10 members that optionally contain one, two or three heteroatoms selected from O, S, NH or N-C1 -8 alkyl; R6 is hydrogen, C1-8 alkyl, O = C-C1-8 alkyl, aryl, aralkyl or C3-10 cycloalkyl; R7 is hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, cycloalkyl which optionally contains a heteroatom selected from O, S, or NR9; and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups may be unsubstituted or substituted by cycloalkyl (or cycloalkyl that optionally contains a heteroatom selected from O, S, or NR9), aryl, aryloxy, heteroaryl, or heteroaryloxy; or R6 and R7 taken together with the N-O to which they are attached can complete a cyclic ring of 5 to 10 members, which optionally contain one, two or three additional heteroatoms selected from O, S, or NR10R11. Useful in the field of pain pain treatment using MEK inhibitors. Chronic pain includes neuropathic pain and chronic inflammation pain.

ARP000103604A 1999-07-16 2000-07-13 METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS. AR024732A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
AR024732A1 true AR024732A1 (en) 2002-10-23

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103604A AR024732A1 (en) 1999-07-16 2000-07-13 METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS.

Country Status (16)

Country Link
EP (1) EP1202726A2 (en)
JP (1) JP2003504400A (en)
KR (1) KR20020012315A (en)
CN (1) CN1373660A (en)
AR (1) AR024732A1 (en)
AU (1) AU5786000A (en)
CA (1) CA2374052A1 (en)
CO (1) CO5300398A1 (en)
HU (1) HUP0202623A3 (en)
IL (1) IL147619A0 (en)
NZ (1) NZ515567A (en)
PE (1) PE20010545A1 (en)
PL (1) PL352684A1 (en)
TR (1) TR200200082T2 (en)
WO (1) WO2001005392A2 (en)
ZA (1) ZA200109907B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230251B1 (en) 2000-07-19 2015-11-30 Warner-Lambert Co. Ester derivatives of 4-iodo phenylamino benzhydroxamic acids and pharmaceutical compositions containing them
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
SI2275102T1 (en) 2002-03-13 2015-12-31 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP4896717B2 (en) 2003-07-24 2012-03-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー N-methyl-substituted benzamidazole
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004279721A1 (en) * 2003-10-08 2005-04-21 Teijin Pharma Limited Process for producing aminopyrrolidine derivative and intermediate compound
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
EP2251327B1 (en) 2003-11-19 2014-02-12 Array Biopharma, Inc. Heterocyclic inhibitors of mek
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
SI1934174T1 (en) 2005-10-07 2011-08-31 Exelixis Inc Azetidines as mek inhibitors for the treatment of proliferative diseases
ES2372955T3 (en) 2006-07-06 2012-01-30 Array Biopharma, Inc. CICLOPENTA [D] PYRIMIDINS AS INHIBITORS OF THE PROTEIN CINASA AKT.
CA2656566C (en) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
TR201900306T4 (en) 2006-12-14 2019-02-21 Exelixis Inc Methods of using Mek inhibitors.
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
JP5542282B2 (en) 2007-07-05 2014-07-09 アレイ バイオファーマ、インコーポレイテッド Pyrimidylcyclopentane as an AKT protein kinase inhibitor
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150089099A (en) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
BRPI0821227A2 (en) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Compound, pharmaceutical composition, method for preparing same, use of a compound, method for treating a disease or disorder, for inhibiting raf function and for inhibiting cell proliferation, inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more more of them
JP5539225B2 (en) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Hydroxylated pyrimidylcyclopentane as an AKT protein kinase inhibitor
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5746630B2 (en) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted sulfonamidophenoxybenzamide
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
JP2013508320A (en) 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト Substituted halophenoxybenzamide derivatives
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CN104945401B (en) 2010-02-01 2017-09-05 癌症研究技术有限公司 IP compounds and their applications in the treatment
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
WO2012135753A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and erlotinib, and methods of use
RU2013148817A (en) 2011-04-01 2015-05-10 Дженентек, Инк. COMBINATIONS OF ACT AND MEK INHIBITOR COMPOUNDS AND WAYS OF THEIR APPLICATION
BR112015008113B1 (en) 2012-10-12 2022-05-24 Exelixis, Inc. New process to prepare compounds for use in cancer treatment
CA2923835C (en) 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US10040769B2 (en) 2015-10-27 2018-08-07 Regenacy Pharmaceuticals, Llc HDAC inhibitors for the treatment of diabetic peripheral neuropathy
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
EP3989957A1 (en) * 2019-06-28 2022-05-04 University of Copenhagen Treatment of cns disorders with sleep disturbances

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
AU756586C (en) * 1997-07-01 2004-01-29 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL132840A (en) * 1997-07-01 2004-12-15 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and pharmaceutical compositions comprising them for use as mek inhibitors
KR100609800B1 (en) * 1998-12-16 2006-08-09 워너-램버트 캄파니 엘엘씨 How to treat arthritis with MEV inhibitor

Also Published As

Publication number Publication date
EP1202726A2 (en) 2002-05-08
CN1373660A (en) 2002-10-09
HUP0202623A3 (en) 2003-03-28
WO2001005392A2 (en) 2001-01-25
ZA200109907B (en) 2003-02-28
PE20010545A1 (en) 2001-06-04
JP2003504400A (en) 2003-02-04
PL352684A1 (en) 2003-09-08
TR200200082T2 (en) 2002-04-22
NZ515567A (en) 2004-03-26
HUP0202623A2 (en) 2002-11-28
AU5786000A (en) 2001-02-05
CO5300398A1 (en) 2003-07-31
CA2374052A1 (en) 2001-01-25
KR20020012315A (en) 2002-02-15
WO2001005392A3 (en) 2001-07-19
IL147619A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
AR024732A1 (en) METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS.
AR016762A1 (en) 4-BROMO OR 4-IODINE PHENYLAMINE BENZOHIDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USE OF THE SAME
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE69930947D1 (en) PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF INTERACTION BETWEEN MDM2 AND MDM2
DK0880508T3 (en) Quinazoline derivatives as VEGF inhibitors
HUP0402376A2 (en) Imidazole-4-carboxamide derivatives, their preparation and pharmaceutical compositions suitable for treatment of obesity containing them
NO972538L (en) New sulfonamides
TW200510353A (en) Alpha substituted carboxylic acids as PPAR modulators
RU2011108563A (en) THALASSEMIA TREATMENT METHODS
EA200500859A1 (en) QUINOLINILPYRROPYRAZOLES
CL2004001167A1 (en) COMPOUNDS DERIVED FROM TIAZOLIDINDIONAS; ELABORATION PROCEDURE: PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE IN THE TREATMENT OF DIABETES.
PT892793E (en) DERIVATIVES 2-CYANOIMINOIMIDAZOLE PDE IV INHIBITORS
TR199701219T1 (en) Benzimidazole compounds, these compounds are Spanish compounds.
BR9307580A (en) Process compounds for the preparation of the same pharmaceutical compositions use of a compound and process for the treatment of a mammal that includes humans
SE9701304D0 (en) Compounds
ES2108027T3 (en) NEW TRICYCLIC COMPOUNDS CONTAINING AMINO AND NITRO, USEFUL AS ACE INHIBITORS.
DE60316672D1 (en) POLYCYCLIC COMPOUNDS AS POTENTIAL ALPHA2 ADRENOCEPTOR ANTAGONISTS
HRP20090264T1 (en) FENIL-PIPERAZIN METANONA DERIVATIVES
PT91435A (en) PROCESS FOR THE PREPARATION OF ARIL-ALKYL AMINES AND -AMIDES HAVING ANTICONVULSIVE AND NEUROPROTECTIVE PROPERTIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES417638A1 (en) PROCEDURE TO PREPARE 2,4,5-TRISUSTITUED OXAZOLES.
ATE246177T1 (en) KATECHOLHYDRAZONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
ES2262504T3 (en) DERIVATIVES OF THE PYROGLUTAMIC ACID AND RELATED COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH THE VLA-4.
DK524283A (en) PROCEDURE FOR NITROSOURE ADDITIVES
FI940568A0 (en) Oxindole-1- (N- (alkoxycarbonyl)) carboxyamides and 1-N-carboxamido) carboxamides as anti-inflammatory agents
SE9702534D0 (en) Compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure